Sodyum bikarbonat etkileşimleri

antasit sınıfından Sodyum bikarbonat (Alka-Seltzer, Neut) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 136 belgelenmiş etkileşim var: 53 majör, 41 orta, 27 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 15 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (53)

  • • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (Akalabrutinib etiketi, İlaç etkileşimleri)

  • Amiloridpotasyum tutucu diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Asetazolamidkarbonik anhidraz inhibitörüMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Atenolol ve klortalidonbeta blokerMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Benazepril ve hidroklorotiyazidACE inhibitörüMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Routine administration of BIXLENVO together with, or 2 hours after, antacids containing Al/Mg is not recommended. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

  • BisakodillaksatifMajör

    …change in bowel habits that lasts more than 2 weeks stomach pain, nausea or vomiting When using this product do not chew or crush tablet(s) do not use within 1 hour after taking an antacid or milk it may cause stomach discomfort, faintness, and cramps Stop use and ask a doctor if you have rectal bleeding or fail to have a bowel movement after use of a laxative. (Bisakodil etiketi, Uyarılar)

  • Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Bumetanidkıvrım (loop) diüretiğiMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • DasatinibMajör

    Antacids: Avoid concomitant use. (Dasatinib etiketi, İlaç etkileşimleri)

  • Deferasiroksdemir takviyesiMajör

    Do not take Exjade with aluminum-containing antacid preparations. (Deferasiroks etiketi, İlaç etkileşimleri)

  • Intervention: Concomitant use of diclofenac sodium/misoprostol and magnesium-containing antacids is not recommended. (Diklofenak ve misoprostol etiketi, İlaç etkileşimleri)

  • DokserkalsiferolD vitamini analoğuMajör

    Examples Magnesium-containing products such as antacids Intervention Avoid use of magnesium-containing products and doxercalciferol in patients on chronic renal dialysis. (Dokserkalsiferol etiketi, İlaç etkileşimleri)

  • EltrombopagOATP1B1 inhibitörüMajör

    Take ALVAIZ at least 2 hours before or 4 hours after any medications or products containing polyvalent cations, such as antacids, dairy products, and mineral supplements to avoid significant reduction in absorption of ALVAIZ due to chelation [see Dosage and Administration ( 2.4 ), Clinical Pharmacology ( 12.3 )] . (Eltrombopag etiketi, İlaç etkileşimleri)

  • Enalapril ve hidroklorotiyazidACE inhibitörüMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Eplerenonaldosteron antagonistiMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Etakrinik asitkıvrım (loop) diüretiğiMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • EtambutolantibiyotikMajör

    It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration. (Etambutol etiketi, İlaç etkileşimleri)

  • FeksofenadinantihistaminikMajör

    When using this product do not take more than directed do not take at the same time as aluminum or magnesium antacids do not take with fruit juices (see Directions) Stop use and ask a doctor if an allergic reaction to this product occurs. (Feksofenadin etiketi, Uyarılar)

  • FenitoinantikonvülsanMajör

    Calcium carbonate, aluminum hydroxide, magnesium hydroxide Prevention or Management: Phenytoin and antacids should not be taken at the same time of day Antineoplastic agents (usually in combination) Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other… (Fenitoin etiketi, İlaç etkileşimleri)

  • Fosinopril ve hidroklorotiyazidACE inhibitörüMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Furosemidkıvrım (loop) diüretiğiMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Hidroklorotiyazidtiyazid diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • İndapamidtiyazid diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Majör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • KalsitriolD vitamini analoğuMajör

    Magnesium-containing preparations (e.g., antacids) and calcitriol should not be used concomitantly in patients on chronic renal dialysis because such use may lead to the development of hypermagnesemia. (Kalsitriol etiketi, Uyarılar)

  • Kalsiyum asetatfosfat bağlayıcıMajör

    Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with calcium acetate capsules. (Kalsiyum asetat etiketi, Uyarılar ve önlemler)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Majör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • • Bile acid sequestering agents and aluminum-based antacids: Avoid concomitant use with CTEXLI. (Kenodeoksikolik asit etiketi, İlaç etkileşimleri)

  • Kinapril ve hidroklorotiyazidACE inhibitörüMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • KininantimalaryalMajör

    Concomitant administration of these antacids with quinine sulfate should be avoided. (Kinin etiketi, İlaç etkileşimleri)

  • Klorotiyazidtiyazid diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Klortalidontiyazid diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Lantanfosfat bağlayıcıMajör

    There is a potential for LANTHANUM CARBONATE to interact with compounds that bind to cationic antacids (i.e., aluminum-, magnesium-, or calcium-based); therefore, do not take such compounds within 2 hours of dosing with LANTHANUM CARBONATE. (Lantan etiketi, İlaç etkileşimleri)

  • Lisinopril ve hidroklorotiyazidACE inhibitörüMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Majör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • MesalazinsalisilatMajör

    Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . (Mesalazin etiketi, İlaç etkileşimleri)

  • Metolazontiyazid diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • NaproksenNSAİİMajör

    Intervention: Concomitant administration of antacids such as magnesium oxide or aluminum hydroxide, and sucralfate with Naproxen Suspension is not recommended. (Naproksen etiketi, İlaç etkileşimleri)

  • NitrofurantoinantibiyotikMajör

    If coadministration of nitrofurantoin with antacids containing magnesium trisilicate cannot be avoided, monitor for lack of efficacy [see Clinical Pharmacology (12.3) ]. (Nitrofurantoin etiketi, İlaç etkileşimleri)

  • OfloksasinflorokinolonMajör

    • that mineral supplements, vitamins with iron or minerals, calcium-, aluminum- or magnesium-based antacids, sucralfate or didanosine chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin (see Drug Interactions ) • that ofloxacin can be taken… (Ofloksasin etiketi, Önlemler)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Majör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Majör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • PazopanibMajör

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib etiketi, İlaç etkileşimleri)

  • RiosiguatvazodilatörMajör

    Antacids: Antacids such as aluminum hydroxide/magnesium hydroxide decrease riociguat absorption and should not be taken within 1 hour of taking Adempas [see Clinical Pharmacology (12.3) ]. (Riosiguat etiketi, İlaç etkileşimleri)

  • Spironolaktonaldosteron antagonistiMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Majör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Torasemidkıvrım (loop) diüretiğiMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Triamterenpotasyum tutucu diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Majör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (41)

  • Amfetamin ve dekstroamfetaminMSS uyarıcısıOrta

    Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (Amfetamin ve dekstroamfetamin etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralOrta

    Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H 2 -receptor antagonists are administered with REYATAZ [see Dosage and Administration ( 2.3 , 2.4 , 2.5 and 2.6) ] . (Atazanavir etiketi, İlaç etkileşimleri)

  • …Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

  • Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (Bosutinib etiketi, İlaç etkileşimleri)

  • Deferiprondemir takviyesiOrta

    Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 ) ] . (Deferipron etiketi, İlaç etkileşimleri)

  • DiflunisalNSAİİOrta

    Antacids Concomitant administration of antacids may reduce plasma levels of diflunisal. (Diflunisal etiketi, İlaç etkileşimleri)

  • Digoksindijital glikozidiOrta

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (Digoksin etiketi, İlaç etkileşimleri)

  • Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitamins cation-containing antacids or laxatives sucralfate buffered medications ↓ elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

  • Drug Interactions Concomitant Drug Class: Drug Name Effect on Concentration Increase = ↑; Decrease = ↓; No Effect = ↔ Clinical Comment Antacids: antacids (e.g., aluminum, magnesium hydroxide, or calcium carbonate) ↔ RPV (antacids taken at least 2 hours before or at least 4 hours after RPV) ↓ RPV (concomitant intake) Administer antacids at least 2 hours before… (Emtrisitabin, rilpivirin ve tenofovir etiketi, İlaç etkileşimleri)

  • For H-2 receptor antagonists and antacids, modify the dosing schedule [see Dosage and Administration (2.4) ]. (Erlotinib etiketi, İlaç etkileşimleri)

  • EtodolakNSAİİOrta

    However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak. (Etodolak etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralOrta

    Antacid: MAALOX TC ↓Amprenavir Use with caution when administered at the same time. (Fosamprenavir etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanOrta

    …Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone,… (Fosfenitoin etiketi, İlaç etkileşimleri)

  • FosinoprilACE inhibitörüOrta

    Antacids In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administrated alone, suggesting that antacids may impair absorption of fosinopril. (Fosinopril etiketi, İlaç etkileşimleri)

  • GabapentinantikonvülsanOrta

    Maalox ® (aluminum hydroxide, magnesium hydroxide) The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox ® ) containing magnesium and aluminum hydroxides. (Gabapentin etiketi, İlaç etkileşimleri)

  • Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (Gefitinib etiketi, İlaç etkileşimleri)

  • HidroksiklorokinQT aralığını uzatan ilaçOrta

    Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (Hidroksiklorokin etiketi, İlaç etkileşimleri)

  • Extravasation: Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site. (Sodyum bikarbonat etiketi, Uyarılar ve önlemler)

  • KinidinantiaritmikOrta

    Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (Kinidin etiketi, İlaç etkileşimleri)

  • KlorokinantimalaryalOrta

    Drug Interactions Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (Klorokin etiketi, İlaç etkileşimleri)

  • Concomitant Drug Class: Drug Name Effect on Concentration ↓ = decrease, ↑ = increase Clinical Comment tenofovir DF = tenofovir disoproxil fumarate Acid Reducing Agents: ↓ ledipasvir Ledipasvir solubility decreases as pH increases. (Ledipasvir ve sofosbuvir etiketi, İlaç etkileşimleri)

  • LevofloksasinflorokinolonOrta

    Interacting Drug Interaction Multivalent cation-containing products including antacids, metal cations or didanosine Absorption of levofloxacin is decreased when the tablet or oral solution formulation is taken within 2 hours of these products. (Levofloksasin etiketi, İlaç etkileşimleri)

  • Lidokainlokal anestezikOrta

    Extravasation: Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site. (Sodyum bikarbonat etiketi, Uyarılar ve önlemler)

  • Lidokain ve adrenalinlokal anestezikOrta

    Extravasation: Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site. (Sodyum bikarbonat etiketi, Uyarılar ve önlemler)

  • Lidokain ve prilokainlokal anestezikOrta

    Extravasation: Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site. (Sodyum bikarbonat etiketi, Uyarılar ve önlemler)

  • Mefenamik asitNSAİİOrta

    Antacid Clinical Impact: Concomitant ingestion of antacids containing magnesium hydroxide has been shown to significantly increase the rate and extent of mefenamic acid absorption [See Clinical Pharmacology ( 12.3 )] Intervention: Concomitant use of mefenamic acid and antacids is not generally recommended because of possible increased adverse events. (Mefenamik asit etiketi, İlaç etkileşimleri)

  • MikofenolatimmünosüpresanOrta

    See FPI for drugs that may interfere with systemic exposure and reduce mycophenolate mofetil efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. (Mikofenolat etiketi, İlaç etkileşimleri)

  • Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Oktreotid etiketi, İlaç etkileşimleri)

  • RanitidinH2 blokeriOrta

    Gefitinib Gefitinib exposure was reduced by 44% with the coadministration of ranitidine and sodium bicarbonate (dosed to maintain gastric pH above 5.0). (Ranitidin etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikOrta

    Quinine Prevention or Management : Avoid concomitant use Decrease AUC by 75%-85% Telithromycin Decrease AUC by 86% Theophylline Decrease exposure by 20%-40% Effect of Other Drugs on Rifampin Concomitant antacid administration may reduce the absorption of rifampin. (Rifampisin etiketi, İlaç etkileşimleri)

  • RilpivirinantiretroviralOrta

    …[see Clinical Pharmacology (12.3) ] Concomitant Drug Class: Drug Name Effect on Concentration of Rilpivirine or Concomitant Drug Clinical Comment ↑=increase, ↓=decrease, ↔=no change Antacids: antacids (e.g., aluminum or magnesium hydroxide, calcium carbonate) ↔ rilpivirine (antacids taken at least 2 hours before or at least 4 hours after rilpivirine) The combination… (Rilpivirin etiketi, İlaç etkileşimleri)

  • RisedronatbifosfonatOrta

    Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (Risedronat etiketi, İlaç etkileşimleri)

  • RosuvastatinstatinOrta

    Table 6: Drug Interactions that Decrease the Efficacy of Rosuvastatin Tablets Antacids Prevention or Management In patients taking an antacid, administer rosuvastatin tablets at least 2 hours before the antacid. (Rosuvastatin etiketi, İlaç etkileşimleri)

  • SefdinirsefalosporinOrta

    Drug Interactions: Antacids (Aluminum- or Magnesium-Containing): Concomitant administration of 300 mg cefdinir capsules with 30 mL Maalox ® TC suspension reduces the rate (C max ) and extent (AUC) of absorption by approximately 40%. (Sefdinir etiketi, İlaç etkileşimleri)

  • SefpodoksimsefalosporinOrta

    Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (Sefpodoksim etiketi, İlaç etkileşimleri)

  • SiprofloksasinflorokinolonOrta

    Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx ® (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products… (Siprofloksasin etiketi, İlaç etkileşimleri)

  • Sodyum polistiren sülfonatpotasyum takviyesiOrta

    Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis ( 7.2 ). (Sodyum polistiren sülfonat etiketi, İlaç etkileşimleri)

  • Clinical Effect/Recommendation Acid Reducing Agents: ↓ velpatasvir Velpatasvir solubility decreases as pH increases. (Sofosbuvir ve velpatasvir etiketi, İlaç etkileşimleri)

  • TadalafilPDE5 inhibitörüOrta

    Antacids — Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduced the apparent rate of absorption of tadalafil without altering exposure (AUC) to tadalafil. (Tadalafil etiketi, İlaç etkileşimleri)

  • TakrolimusimmünosüpresanOrta

    Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions ( 5.7 , 5.10 , 5.11 )]. (Takrolimus etiketi, İlaç etkileşimleri)

  • TrospiyumantikolinerjikOrta

    Exposure to trospium on average was comparable in the presence of and without antacid, however, some individuals demonstrated increases or decreases in trospium exposure in the presence of antacid. (Trospiyum etiketi, İlaç etkileşimleri)

Minör değinmeler (27)

  • AlendronatbifosfonatMinör

    Calcium supplements, antacids or oral medications containing multivalent cations interfere with absorption of alendronate. (Alendronat etiketi, İlaç etkileşimleri)

  • Baloksavir marboksilantiviralMinör

    Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). (Baloksavir marboksil etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralMinör

    …drug-drug interactions have not been observed or are not anticipated with concomitant use of darunavir and cobicistat with rilpivirine, dolutegravir, raltegravir, abacavir, emtricitabine, emtricitabine/tenofovir alafenamide, tenofovir DF, lamivudine, stavudine, zidovudine, or acid modifying medications (antacids, H 2 -receptor antagonists, proton pump inhibitors). (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

  • DekstroamfetaminMSS uyarıcısıMinör

    Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (Dekstroamfetamin etiketi, İlaç etkileşimleri)

  • Demeklosiklintetrasiklin antibiyotikMinör

    Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations. (Demeklosiklin etiketi, İlaç etkileşimleri)

  • DiazepambenzodiazepinMinör

    Antacids Diazepam peak concentrations are 30% lower when antacids are administered concurrently. (Diazepam etiketi, İlaç etkileşimleri)

  • DisikloverinantikolinerjikMinör

    Antacids: interfere with the absorption of anticholinergic agents (7) (Disikloverin etiketi, İlaç etkileşimleri)

  • Doksisiklintetrasiklin antibiyotikMinör

    Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. (Doksisiklin etiketi, İlaç etkileşimleri)

  • DolutegravirantiretroviralMinör

    TIVICAY or TIVICAY PD should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. (Dolutegravir etiketi, İlaç etkileşimleri)

  • HiyosiyaminantikolinerjikMinör

    Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride. (Hiyosiyamin etiketi, İlaç etkileşimleri)

  • İbandronatbifosfonatMinör

    Calcium supplements, antacids and some oral medications may interfere with absorption of ibandronate. (İbandronat etiketi, İlaç etkileşimleri)

  • KabotegravirantiretroviralMinör

    Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment Antacids containing polyvalent cations (e.g., aluminum or magnesium hydroxide, calcium carbonate) ↓Cabotegravir Administer antacid products at least 2 hours before or 4 hours after taking VOCABRIA. (Kabotegravir etiketi, İlaç etkileşimleri)

  • KetoprofenNSAİİMinör

    It is possible that minor adverse symptoms of gastric intolerance may be prevented by administering Ketoprofen Capsules, USP with antacids, food, or milk. (Ketoprofen etiketi, Uyarılar ve önlemler)

  • LaktulozlaksatifMinör

    Drug Interactions Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. (Laktuloz etiketi, İlaç etkileşimleri)

  • LapatinibP-glikoprotein inhibitörüMinör

    Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (Lapatinib etiketi, İlaç etkileşimleri)

  • MemantinMinör

    Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). (Memantin etiketi, İlaç etkileşimleri)

  • Memantin ve donepezilkolinesteraz inhibitörüMinör

    Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (Memantin ve donepezil etiketi, İlaç etkileşimleri)

  • MetskopolaminantikolinerjikMinör

    Concomitant administration with antacids may interfere with the absorption of methscopolamine bromide. (Metskopolamin etiketi, İlaç etkileşimleri)

  • MiglitolantidiyabetikMinör

    In 12 healthy males, concomitantly administered antacid did not influence the pharmacokinetics of miglitol. (Miglitol etiketi, İlaç etkileşimleri)

  • Minosiklintetrasiklin antibiyotikMinör

    Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. (Minosiklin etiketi, İlaç etkileşimleri)

  • Raloksifenselektif östrojen reseptör modülatörüMinör

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (Raloksifen etiketi, İlaç etkileşimleri)

  • RaltegravirantiretroviralMinör

    Table 8: Selected Drug Interactions in Adults Concomitant Drug Class: Drug Name Effect on Concentration of Raltegravir Clinical Comment Metal-Containing Antacids aluminum and/or magnesium-containing antacids ↓ Coadministration or staggered administration of aluminum and/or magnesium hydroxide-containing antacids and ISENTRESS is not recommended. (Raltegravir etiketi, İlaç etkileşimleri)

  • SefaklorsefalosporinMinör

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (Sefaklor etiketi, İlaç etkileşimleri)

  • SefuroksimsefalosporinMinör

    Administer cefuroxime axetil at least 1 hour before or 2 hours after administration of short-acting antacids. (Sefuroksim etiketi, İlaç etkileşimleri)

  • Tetrasiklintetrasiklin antibiyotikMinör

    Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate. (Tetrasiklin etiketi, İlaç etkileşimleri)

  • Aluminum-based Antacids : May interfere with the action of URSO 250 and URSO Forte by reducing its absorption. (Ursodeoksikolik asit etiketi, İlaç etkileşimleri)

  • VardenafilPDE5 inhibitörüMinör

    Other Drug Interactions No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, an antacid based on magnesium-aluminum hydroxide, and ranitidine. (Vardenafil etiketi, İlaç etkileşimleri)

Anlamlı etkileşim olmadığı bildirilenler (15)

  • DofetilidantiaritmikEtkileşim yok

    If a patient requires dofetilide and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of dofetilide. (Dofetilid etiketi, İlaç etkileşimleri)

  • DoravirinantiretroviralEtkileşim yok

    …clinically significant changes in concentration were observed for doravirine when co-administered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see Clinical Pharmacology (12.3) ]. (Doravirin etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralEtkileşim yok

    Drugs Without Clinically Significant Interactions with Efavirenz No dosage adjustment is recommended when efavirenz is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lorazepam, nelfinavir, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine, stavudine, tenofovir… (Efavirenz etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralEtkileşim yok

    Drugs without Clinically Significant Interactions No dosage adjustment is recommended when SYMFI is administered with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, and lorazepam. (Efavirenz, lamivudin ve tenofovir etiketi, İlaç etkileşimleri)

  • FamsiklovirantiviralEtkileşim yok

    …Penciclovir No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. (Famsiklovir etiketi, İlaç etkileşimleri)

  • FelbamatantikonvülsanEtkileşim yok

    Effects of Antacids on Felbatol ® The rate and extent of absorption of a 2400 mg dose of Felbatol ® as monotherapy given as tablets was not affected when coadministered with antacids. (Felbamat etiketi, İlaç etkileşimleri)

  • KlorazepatbenzodiazepinEtkileşim yok

    In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of clorazepate dipotassium tablets. (Klorazepat etiketi, İlaç etkileşimleri)

  • NabumetonNSAİİEtkileşim yok

    Concomitant administration of an aluminum-containing antacid had no significant effect on the bioavailability of 6MNA. (Nabumeton etiketi, İlaç etkileşimleri)

  • OlanzapinantipsikotikEtkileşim yok

    Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine. (Olanzapin etiketi, İlaç etkileşimleri)

  • OseltamivirantiviralEtkileşim yok

    …Clinically Significant Drug Interaction with TAMIFLU No dose adjustments are needed for either oseltamivir or the concomitant drug when coadministering oseltamivir with amoxicillin, acetaminophen, aspirin, cimetidine, antacids (magnesium and aluminum hydroxides and calcium carbonates), rimantadine, amantadine, or warfarin [see Clinical Pharmacology (12.3) ] . (Oseltamivir etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalEtkileşim yok

    No clinically relevant effects on the pharmacokinetics of Noxafil delayed-release tablets were observed during concomitant use with antacids, H 2 -receptor antagonists and proton pump inhibitors, and metoclopramide [see Clinical Pharmacology (12.3) ] . (Posakonazol etiketi, İlaç etkileşimleri)

  • SefprozilsefalosporinEtkileşim yok

    The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid. (Sefprozil etiketi, İlaç etkileşimleri)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Etkileşim yok

    The following have no clinically relevant effects on the pharmacokinetics of amlodipine: cimetidine, grapefruit juice, magnesium and aluminum hydroxide antacid, sildenafil. (Telmisartan ve amlodipin etiketi, İlaç etkileşimleri)

  • Valproik asitantikonvülsanEtkileşim yok

    Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Antacids A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate. (Valproik asit etiketi, İlaç etkileşimleri)

  • ZiprasidonantipsikotikEtkileşim yok

    Antacid The co-administration of 30 mL of Maalox® with ziprasidone did not affect the pharmacokinetics of ziprasidone. (Ziprasidon etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Sodyum bikarbonat ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.